FDA: Tysabri risks greatest during year 3

A board to discuss the newly-released drug Tysabri, (formerly known as Antegren) as a treatment for Multiple Sclerosis

FDA: Tysabri risks greatest during year 3

Postby MSUK » Mon Apr 25, 2011 11:29 pm


The FDA has updated its warning on Biogen Idec's multiple sclerosis drug Tysabri. According to the agency, the risk of a potentially fatal brain infection appears to be greatest during the third year of treatment.

Since Tysabri was reintroduced in 2006, Biogen and the FDA have been keeping close tabs on cases of progressive multifocal leukoencephalopathy, or PML. Biogen regularly updates case counts, and the FDA has been estimating the cumulative risk posed by the drug. This is the first time the agency has calculated PML risk according to specific time intervals. The newly sliced data is designed to help doctors "better assess risk based on duration of treatment," the agency said....Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1905
MS-UK - http://www.ms-uk.org/
User avatar
Family Elder
Posts: 2501
Joined: Wed Oct 14, 2009 2:00 pm


Return to Tysabri (Antegren or Natalizumab)


  • Related topics
    Last post

Who is online

Users browsing this forum: No registered users

Contact us | Terms of Service